

Eric J Roeland

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4155174/publications.pdf>

Version: 2024-02-01

179
papers

2,946
citations

236925

25
h-index

197818

49
g-index

183
all docs

183
docs citations

183
times ranked

4272
citing authors

#	ARTICLE	IF	CITATIONS
1	Caregiver Reported Quality of End-of-Life Care of Adolescent and Young Adult Decedents With Cancer. <i>Journal of Palliative Care</i> , 2022, 37, 87-92.	1.0	5
2	Neoadjuvant versus Postoperative Chemoradiotherapy is Associated with Improved Survival for Patients with Resectable Gastric and Gastroesophageal Cancer. <i>Annals of Surgical Oncology</i> , 2022, 29, 242-252.	1.5	4
3	Evaluating the incidence of chemotherapy-induced nausea and vomiting in patients with B-cell lymphoma receiving dose-adjusted EPOCH and rituximab. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 119-126.	0.9	2
4	Percentile-based averaging and skeletal muscle gauge improve body composition analysis: validation at multiple vertebral levels. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2022, 13, 190-202.	7.3	13
5	Missing Voices: Lessons Learned from Nonparticipating Caregivers in Palliative Care Research. <i>Journal of Palliative Medicine</i> , 2022, 25, 455-460.	1.1	1
6	Associations of sarcopenia with hematologic toxicity, treatment intensity, and healthcare utilization in patients with metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 84-84.	1.6	1
7	A phase II study of niraparib and dostarlimab with radiation in patients with metastatic pancreatic cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 564-564.	1.6	0
8	Addressing unmet needs for people with cancer cachexia: recommendations from a multistakeholder workshop. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2022, 13, 1418-1425.	7.3	19
9	Bereaved Caregivers Perspectives of Negative Communication Experiences Near the End of Life for Adolescents and Young Adults with Cancer. <i>Journal of Adolescent and Young Adult Oncology</i> , 2022, 11, 498-505.	1.3	4
10	Cancer cachexia: the elephant in the room?. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2022, 13, 3-4.	7.3	8
11	Leading from the Heart. <i>Journal of Pain and Symptom Management</i> , 2022, 63, e645-e646.	1.2	1
12	Changes in Functional Assessment of Cancer Therapy: General (FACT-G) to predict treatment response and survival outcomes in patients with metastatic gastrointestinal (GI) cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 6570-6570.	1.6	0
13	Supportive Oncology Care at Home Intervention for Patients With Pancreatic Cancer. <i>JCO Oncology Practice</i> , 2022, 18, e1587-e1593.	2.9	6
14	FIT: Functional and imaging testing for patients with metastatic cancer. <i>Supportive Care in Cancer</i> , 2021, 29, 2771-2775.	2.2	2
15	Efficacy of intravenous NEPA, a fixed NK1/5-HT3 receptor antagonist combination, for the prevention of chemotherapy-induced nausea and vomiting (CINV) during cisplatin- and anthracycline cyclophosphamide (AC)-based chemotherapy: A review of phase 3 studies. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103143.	4.4	5
16	Associations of baseline patient-reported outcomes with treatment outcomes in advanced gastrointestinal cancer. <i>Cancer</i> , 2021, 127, 619-627.	4.1	7
17	Avoidable Acute Care Use Associated with Nausea and Vomiting Among Patients Receiving Highly Emetogenic Chemotherapy or Oxaliplatin. <i>Oncologist</i> , 2021, 26, 325-331.	3.7	11
18	Cost Savings Associated With Palliative Care Among Older Adults With Advanced Cancer. <i>American Journal of Hospice and Palliative Medicine</i> , 2021, 38, 1250-1257.	1.4	10

#	ARTICLE	IF	CITATIONS
19	Exploring the Expanded Role of Pharmacists in Advance Care Planning. JCO Oncology Practice, 2021, 17, 102-106.	2.9	3
20	The Impact of Early Referrals to Dietitians for Patients With Esophagogastric Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 235-238.	4.9	2
21	Associations of Skeletal Muscle With Symptom Burden and Clinical Outcomes in Hospitalized Patients With Advanced Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 319-327.	4.9	10
22	Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer. Clinical Cancer Research, 2021, 27, 5586-5594.	7.0	178
23	Management of Dyspnea in Advanced Cancer: ASCO Guideline. Journal of Clinical Oncology, 2021, 39, 1389-1411.	1.6	74
24	Healthcare utilization and costs associated with cancer-related diarrhea.. Journal of Clinical Oncology, 2021, 39, e18623-e18623.	1.6	2
25	Muscle Loss Is Associated with Overall Survival in Patients with Metastatic Colorectal Cancer Independent of Tumor Mutational Status and Weight Loss. Oncologist, 2021, 26, e963-e970.	3.7	9
26	The impact of cancer-related diarrhea on changes in cancer therapy patterns.. Journal of Clinical Oncology, 2021, 39, 12111-12111.	1.6	0
27	Changes in patient-reported outcomes (PROs) and tumor markers (TMs) to predict treatment response and survival outcomes in patients with metastatic gastrointestinal (GI) cancer.. Journal of Clinical Oncology, 2021, 39, 6560-6560.	1.6	0
28	Characterizing unplanned resource utilization associated with cancer-related diarrhea.. Journal of Clinical Oncology, 2021, 39, e18625-e18625.	1.6	0
29	Care Patterns and Overall Survival in Patients With Early-Onset Metastatic Colorectal Cancer. JCO Oncology Practice, 2021, 17, e1846-e1855.	2.9	9
30	Clinical and mutational profile of ARID1A-mutated gastrointestinal cancers: Duration of response to platinum-based chemotherapy.. Journal of Clinical Oncology, 2021, 39, e15611-e15611.	1.6	1
31	Supportive oncology care at home intervention for patients with pancreatic cancer.. Journal of Clinical Oncology, 2021, 39, 6558-6558.	1.6	2
32	Assessing duration of breakthrough chemotherapy-induced nausea and vomiting (CINV): A pooled study analysis of NEPA versus aprepitant.. Journal of Clinical Oncology, 2021, 39, 12091-12091.	1.6	0
33	Early Weight Loss as a Prognostic Factor in Patients with Advanced Gastric Cancer: Analyses from <scp>REGARD</scp>, <scp>RAINBOW</scp>, and <scp>RAINFALL</scp> Phase <scp>III</scp> Studies. Oncologist, 2021, 26, e1538-e1547.	3.7	19
34	Results and Molecular Correlates from a Pilot Study of Neoadjuvant Induction FOLFIRINOX Followed by Chemoradiation and Surgery for Gastroesophageal Adenocarcinomas. Clinical Cancer Research, 2021, 27, 6343-6353.	7.0	8
35	Important news on nutritional support in cancer patients “ but some EFFORT is still ahead. Annals of Oncology, 2021, 32, 954-956.	1.2	1
36	Single-dose netupitant/palonosetron versus 3-day aprepitant for preventing chemotherapy-induced nausea and vomiting: a pooled analysis. Future Oncology, 2021, 17, 3027-3035.	2.4	8

#	ARTICLE	IF	CITATIONS
37	ASO Visual Abstract: Neoadjuvant versus Postoperative Chemoradiotherapy Is Associated with Improved Survival in Patients with Resectable Gastric and Gastroesophageal Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 690-691.	1.5	0
38	Leveraging patient-reported outcomes (PROs) in patients with pancreatic cancer: The Pancreatic Cancer Action Network (PanCAN) online patient registry experience. <i>Cancer Medicine</i> , 2021, 10, 7152-7161.	2.8	6
39	1696TiP Phase Ib study to assess the effect of PF-06946860 on appetite following subcutaneous administration in patients with anorexia and advanced cancer. <i>Annals of Oncology</i> , 2021, 32, S1185.	1.2	2
40	Supportive oncology care at home intervention for patients with pancreatic cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 155-155.	1.6	2
41	Changes in patient-reported outcomes (PROs) and tumor markers (TMs) to predict treatment response and survival in patients with metastatic gastrointestinal (GI) cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 154-154.	1.6	0
42	Barriers to Optimal End-of-Life Care for Adolescents and Young Adults With Cancer: Bereaved Caregiver Perspectives. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 528-533.	4.9	20
43	More opioids, more constipation? Evaluation of longitudinal total oral opioid consumption and self-reported constipation in patients with cancer. <i>Supportive Care in Cancer</i> , 2020, 28, 1793-1797.	2.2	6
44	End-of-life care among adolescent and young adult patients with cancer living in poverty. <i>Cancer</i> , 2020, 126, 886-893.	4.1	24
45	Impact of Addition of Carboplatin AUC ≥ 4 to Antiemetic Guidelines for Triple Antiemetic Prophylaxis: A Gap in Quality of Care, Guideline Adoption, and Avoiding Acute Care. <i>JCO Oncology Practice</i> , 2020, 16, e132-e138.	2.9	3
46	Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy. <i>Oncologist</i> , 2020, 25, e589-e597.	3.7	21
47	Computed Tomography-based Body Composition Analysis and Its Role in Lung Cancer Care. <i>Journal of Thoracic Imaging</i> , 2020, 35, 91-100.	1.5	39
48	Revisiting MET: Clinical Characteristics and Treatment Outcomes of Patients with Locally Advanced or Metastatic, MET-Amplified Esophagogastric Cancers. <i>Oncologist</i> , 2020, 25, e1691-e1700.	3.7	1
49	Reply to O. Huillard et al. <i>Journal of Clinical Oncology</i> , 2020, 38, 3819-3819.	1.6	2
50	Unscheduled hydrations: redefining complete response in chemotherapy-induced nausea and vomiting studies. <i>Future Oncology</i> , 2020, 16, 1863-1872.	2.4	5
51	Total Neoadjuvant Therapy versus Neoadjuvant Chemoradiotherapy in the Management of Gastric Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, e602-e603.	0.8	0
52	Neoadjuvant versus Postoperative Chemoradiotherapy in Gastric Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, e632.	0.8	0
53	Management of Cancer Cachexia: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2020, 38, 2438-2453.	1.6	292
54	Multisite, Randomized Trial of Early Integrated Palliative and Oncology Care in Patients with Advanced Lung and Gastrointestinal Cancer: Alliance A221303. <i>Journal of Palliative Medicine</i> , 2020, 23, 922-929.	1.1	31

#	ARTICLE	IF	CITATIONS
55	Impact of Postoperative Complication and Completion of Multimodality Therapy on Survival in Patients Undergoing Gastrectomy for Advanced Gastric Cancer. <i>Journal of the American College of Surgeons</i> , 2020, 230, 912-924.	0.5	42
56	Leveraging the Potential Synergy Between Patient-Reported Outcomes and Body Composition Analysis in Patients with Cancer. <i>Oncologist</i> , 2020, 25, 271-273.	3.7	7
57	Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers. <i>Clinical Cancer Research</i> , 2020, 26, 1877-1885.	7.0	67
58	Analysis of weight loss as a prognostic factor in patients (pts) with advanced gastric cancer from REGARD, RAINBOW and RAINFALL phase III studies.. <i>Journal of Clinical Oncology</i> , 2020, 38, 348-348.	1.6	1
59	Noninvasive comprehensive genomic profiling from plasma ctDNA in pancreatic cancer patients.. <i>Journal of Clinical Oncology</i> , 2020, 38, 753-753.	1.6	1
60	What the HEC? Clinician Adherence to Evidence-Based Antiemetic Prophylaxis for Highly Emetogenic Chemotherapy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 676-681.	4.9	18
61	The role of circulating tumor DNA (ctDNA), tumor markers (TMs), and patient-reported outcomes (PROs) in predicting treatment response in patients with metastatic gastrointestinal (GI) cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 833-833.	1.6	0
62	Abstract P5-14-07: Avoidable acute care involving chemotherapy-induced nausea and vomiting (CINV) among patients with breast cancer receiving anthracycline + cyclophosphamide (AC) with NEPA prophylaxis relative to other antiemetics: An external control arm analysis. , 2020, , .		1
63	Work loss and activity impairment due to duration of nausea and vomiting in patients with breast cancer receiving CINV prophylaxis.. <i>Journal of Clinical Oncology</i> , 2020, 38, e24133-e24133.	1.6	4
64	Relationships among skeletal muscle, symptom burden, health care use, and survival in hospitalized patients with advanced cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 7006-7006.	1.6	0
65	Preliminary analysis of total neoadjuvant therapy for patients with locally advanced gastric (G) and gastroesophageal (GE) adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 393-393.	1.6	1
66	Leveraging patient-reported outcomes (PROs) in patients with pancreatic cancer: The Pancreatic Cancer Action Network (PanCAN) online patient registry experience.. <i>Journal of Clinical Oncology</i> , 2020, 38, 154-154.	1.6	2
67	Use of patient-reported outcomes (PROs) to predict treatment outcomes in patients with advanced cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 186-186.	1.6	0
68	Top Ten Tips Palliative Care Clinicians Should Know About Caring for Patients with Hematologic Malignancies. <i>Journal of Palliative Medicine</i> , 2019, 22, 1449-1454.	1.1	8
69	Analysis of weight loss as a prognostic factor in patients with advanced gastric cancer from the Phase 3 RAINBOW study. <i>Annals of Oncology</i> , 2019, 30, iv111.	1.2	0
70	Serial circulating tumor DNA (ctDNA) monitoring to predict response to treatment in metastatic gastrointestinal cancers. <i>Annals of Oncology</i> , 2019, 30, iv112.	1.2	1
71	PARP-ness in metastatic colorectal cancer. <i>Annals of Oncology</i> , 2019, 30, iv117.	1.2	2
72	Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. <i>Nature Medicine</i> , 2019, 25, 1415-1421.	30.7	359

#	ARTICLE	IF	CITATIONS
73	A Pilot Study of Neoadjuvant FOLFIRINOX followed by Chemoradiation for Gastric and Gastroesophageal Cancer: Preliminary Results and Prognostic Implications of ctDNA. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, S85-S86.	0.8	4
74	The Cambia Sojourns Scholars Leadership Program: Projects and Reflections on Leadership in Palliative Care. <i>Journal of Palliative Medicine</i> , 2019, 22, 823-829.	1.1	3
75	What's the Deal with Blood Cancers? Navigating a New Frontier in Palliative Cancer Care (TH313). <i>Journal of Pain and Symptom Management</i> , 2019, 57, 371.	1.2	0
76	Physician concordance with update to ASCO guidelines for antiemetic use with carboplatin AUC ≥ 4 .. <i>Journal of Clinical Oncology</i> , 2019, 37, 11595-11595.	1.6	2
77	A pilot study of neoadjuvant FOLFIRINOX followed by chemoradiation for gastric and gastroesophageal cancer: Preliminary results.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4057-4057.	1.6	4
78	BPI19-019: Avoidable Acute Care Use Associated With Nausea and Vomiting Among Patients Receiving Highly Emetogenic Chemotherapy or Oxaliplatin. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, BPI19-019.	4.9	2
79	Abstract P4-16-05: Avoidable acute care use associated with nausea and emesis among patients receiving AC, carboplatin, or cisplatin for breast cancer. , 2019, , .		0
80	Potentially avoidable acute care use among patients receiving oxaliplatin.. <i>Journal of Clinical Oncology</i> , 2019, 37, 651-651.	1.6	0
81	Ondansetron versus palonosetron as a marker of non-adherence to antiemetic prophylaxis guidelines in highly emetogenic chemotherapy.. <i>Journal of Clinical Oncology</i> , 2019, 37, e23108-e23108.	1.6	0
82	Aggressiveness of care and overall survival in young metastatic colorectal cancer patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3563-3563.	1.6	2
83	Abstract LB-257: Liquid biopsy versus tissue biopsy to assess acquired resistance and tumor heterogeneity in gastrointestinal cancers. , 2019, , .		0
84	Acute care and hydration due to chemotherapy-induced nausea and vomiting (CINV) among patients receiving NEPA prophylaxis for anthracycline + cyclophosphamide (AC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 112-112.	1.6	2
85	Top Ten Tips for Palliative Care Clinicians Caring for Cancer Patients Receiving Immunotherapies. <i>Journal of Palliative Medicine</i> , 2018, 21, 694-699.	1.1	9
86	Pain Syndromes and Management in Adult Hematopoietic Stem Cell Transplantation. <i>Hematology/Oncology Clinics of North America</i> , 2018, 32, 551-567.	2.2	15
87	Transfusion practices at end of life for hematopoietic stem cell transplant patients. <i>Supportive Care in Cancer</i> , 2018, 26, 1927-1931.	2.2	8
88	Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy. <i>Annals of Oncology</i> , 2018, 29, 1535-1540.	1.2	27
89	What do transplant physicians think about palliative care? A national survey study. <i>Cancer</i> , 2018, 124, 4556-4566.	4.1	47
90	Opioid and Benzodiazepine Relative Use in Breast Cancer Patients Before, During, and After Curative Chemotherapy. <i>Journal of Pain and Palliative Care Pharmacotherapy</i> , 2018, 32, 27-29.	0.8	5

#	ARTICLE	IF	CITATIONS
91	Evaluation of Cost of Hospitalizations Related to Nausea and Vomiting Among Cancer Patients. Value in Health, 2018, 21, S27.	0.3	0
92	A National Survey Study of Transplant Physicians' Attitudes About Palliative Care. Biology of Blood and Marrow Transplantation, 2018, 24, S59-S60.	2.0	0
93	Evidence-based Palliative Care Approaches to Non-pain Physical Symptom Management in Cancer Patients. Seminars in Oncology Nursing, 2018, 34, 227-240.	1.5	17
94	Efficacy of an intravenous formulation of NEPA, a fixed combination of fosnetupitant and palonosetron, compared with oral NEPA studies in the prevention of chemotherapy-induced nausea and vomiting (CINV): An analysis of 1026 patient experiences.. Journal of Clinical Oncology, 2018, 36, e22177-e22177.	1.6	2
95	Inpatient hospitalization costs associated with nausea and vomiting among patients with cancer.. Journal of Clinical Oncology, 2018, 36, 112-112.	1.6	4
96	What the HEC? Physician variation and attainable compliance targets in antiemetic prophylaxis.. Journal of Clinical Oncology, 2018, 36, 74-74.	1.6	2
97	Efficacy of intravenous (IV) NEPA, a fixed NK1/5-HT3 receptor antagonist combination, for prevention of emesis following highly emetogenic chemotherapy (HEC).. Journal of Clinical Oncology, 2018, 36, 194-194.	1.6	4
98	More opioids, more constipation? Evaluation of longitudinal total oral opioid consumption and self-reported constipation in patients with cancer.. Journal of Clinical Oncology, 2018, 36, 211-211.	1.6	1
99	CACHEXIO: Evaluation of body composition changes and immunotherapy in patients with metastatic cancer.. Journal of Clinical Oncology, 2018, 36, 209-209.	1.6	2
100	The impact of emergency general surgery on end-of-life care among older patients with metastatic cancer.. Journal of Clinical Oncology, 2018, 36, 56-56.	1.6	2
101	FIT: Functional and imaging testing for patients with metastatic cancer.. Journal of Clinical Oncology, 2018, 36, 208-208.	1.6	5
102	Concordance Between Veterans' Self-Report and Documentation of Surrogate Decision Makers: Implications for Quality Measurement. Journal of Pain and Symptom Management, 2017, 53, 1-4.	1.2	11
103	Operationalizing the Measuring What Matters Spirituality Quality Metric in a Population of Hospitalized, Critically Ill Patients and Their Family Members. Journal of Pain and Symptom Management, 2017, 53, 650-655.	1.2	19
104	Tailoring Palliative Care to the Changing Needs of People Facing Cancer. Journal of Clinical Oncology, 2017, 35, 813-815.	1.6	9
105	The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting. Annals of Oncology, 2017, 28, 1260-1267.	1.2	134
106	Patient-Controlled Analgesia for Cancer-Related Pain: Clinical Predictors of Patient Outcomes. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 595-600.	4.9	5
107	A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia. Journal of Hematology and Oncology, 2017, 10, 73.	17.0	57
108	The Implementation of Measuring What Matters in Research and Practice: Series Commentary. Journal of Pain and Symptom Management, 2017, 54, 772-775.	1.2	6

#	ARTICLE	IF	CITATIONS
109	Early Palliative Care for Patients with Hematologic Malignancies: Is It Really so Difficult to Achieve?. Current Hematologic Malignancy Reports, 2017, 12, 300-308.	2.3	66
110	NCCN Guidelines Insights: Antiemesis, Version 2.2017. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 883-893.	4.9	137
111	Weight loss versus muscle loss: re-evaluating inclusion criteria for future cancer cachexia interventional trials. Supportive Care in Cancer, 2017, 25, 365-369.	2.2	31
112	Addressing Hereditary Cancer Risk at the End of Life. Journal of Oncology Practice, 2017, 13, e851-e856.	2.5	10
113	Advance Care Planning and Palliative Care Integration for Patients Undergoing Hematopoietic Stem-Cell Transplantation. Journal of Oncology Practice, 2017, 13, e721-e728.	2.5	24
114	Managing Malignant Bowel Obstruction: Moving Beyond Drip and Suck. Journal of Oncology Practice, 2017, 13, 437-438.	2.5	2
115	Effect of Palliative Care on Aggressiveness of End-of-Life Care Among Patients With Advanced Cancer. Journal of Oncology Practice, 2017, 13, e760-e769.	2.5	61
116	Evaluation of daily breakthrough chemotherapy-induced nausea and vomiting (CINV) rates in a phase III study of NEPA versus an aprepitant (APR)/granisetron (GRAN) regimen.. Journal of Clinical Oncology, 2017, 35, 120-120.	1.6	4
117	Hospitalization costs for nausea and vomiting: A savings opportunity.. Journal of Clinical Oncology, 2017, 35, 155-155.	1.6	8
118	Administration of the ASCO Pain Survey to identify patient education deficiencies in patients with cancer.. Journal of Clinical Oncology, 2017, 35, 68-68.	1.6	0
119	Palliative care pharmacists as advocates to conduct advance care planning.. Journal of Clinical Oncology, 2017, 35, 73-73.	1.6	0
120	Next-generation sequencing ordering trends in the cancer trajectory.. Journal of Clinical Oncology, 2017, 35, 10104-10104.	1.6	0
121	Advance care planning in Hispanic/Latino and non-Hispanic white patients with cancer.. Journal of Clinical Oncology, 2017, 35, 10-10.	1.6	1
122	Economic impact of palliative care among elderly cancer patients.. Journal of Clinical Oncology, 2017, 35, 91-91.	1.6	3
123	The Default Dilemma: Code Status Regardless of Medical Context. Journal of Palliative Medicine, 2016, 19, 1134-1134.	1.1	0
124	Cancer Cachexia: Beyond Weight Loss. Journal of Oncology Practice, 2016, 12, 1163-1171.	2.5	162
125	Exploring the Definition of an Informed Health Care Proxy. Journal of Palliative Medicine, 2016, 19, 250-251.	1.1	4
126	Patterns of Palliative Care Consultation Among Elderly Patients With Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 439-445.	4.9	52

#	ARTICLE	IF	CITATIONS
127	Palliative chemotherapy: oxymoron or misunderstanding?. BMC Palliative Care, 2016, 15, 33.	1.8	31
128	Patient-Controlled Analgesia for Cancer-Related Pain: Clinical Predictors of Patient Outcomes (S785). Journal of Pain and Symptom Management, 2016, 51, 454-455.	1.2	0
129	Feeling Heard and Understood: A Patient-Reported Quality Measure for the Inpatient Palliative Care Setting. Journal of Pain and Symptom Management, 2016, 51, 150-154.	1.2	48
130	Concordance of Advance Care Plans With Inpatient Directives in the Electronic Medical Record for Older Patients Admitted From the Emergency Department. Journal of Pain and Symptom Management, 2016, 51, 647-651.	1.2	39
131	Assessing Emotional Suffering in Palliative Care: Use of a Structured Note Template to Improve Documentation. Journal of Pain and Symptom Management, 2016, 52, 1-7.	1.2	15
132	Adherence to Measuring What Matters Items When Caring for Patients With Hematologic Malignancies Versus Solid Tumors. Journal of Pain and Symptom Management, 2016, 52, 775-782.	1.2	15
133	Adherence to Measuring What Matters Measures Using Point-of-Care Data Collection Across Diverse Clinical Settings. Journal of Pain and Symptom Management, 2016, 51, 497-503.	1.2	17
134	Advance care planning and palliative care consultation for stem cell transplant patients.. Journal of Clinical Oncology, 2016, 34, 113-113.	1.6	4
135	Code status documentation in the electronic medical record for patients with stage IV pancreatic cancer.. Journal of Clinical Oncology, 2016, 34, 125-125.	1.6	0
136	Molecular tumor profiling ordering trends in cancer patients.. Journal of Clinical Oncology, 2016, 34, 165-165.	1.6	1
137	Palliative care and health care utilization at the end of life.. Journal of Clinical Oncology, 2016, 34, 152-152.	1.6	1
138	Blood transfusions at end of life for stem cell transplant patients.. Journal of Clinical Oncology, 2016, 34, 115-115.	1.6	1
139	Chemotherapy-Induced Nausea and Vomiting (CINV) in Hematologic Malignancy Patients Receiving Multi-Day Highly Emetogenic Chemotherapy (HEC). Blood, 2016, 128, 2410-2410.	1.4	1
140	1590 Patient-related factors in determining the emetic risk potential for patients undergoing chemotherapy: An evaluation of predictive models for the development of a risk assessment tool. European Journal of Cancer, 2015, 51, S234.	2.8	0
141	Spanning the canyon between stem cell transplantation and palliative care. Hematology American Society of Hematology Education Program, 2015, 2015, 484-489.	2.5	21
142	Enhancing legacy in palliative care: study protocol for a randomized controlled trial of Dignity Therapy focused on positive outcomes. BMC Palliative Care, 2015, 14, 44.	1.8	11
143	A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies. Supportive Care in Cancer, 2015, 23, 2231-2244.	2.2	25
144	The Polypharmacy Police Versus the Patient Advocate: An Evidence-Based, Patient-Tailored Approach to Medication Simplification Strategies for the Palliative Care Patient (SA517). Journal of Pain and Symptom Management, 2015, 49, 395-396.	1.2	0

#	ARTICLE	IF	CITATIONS
145	Titrate to Death? Prescribing Patterns of Continuous Morphine Infusions at End of Life (S758). <i>Journal of Pain and Symptom Management</i> , 2015, 49, 437.	1.2	0
146	Olanzapine in the Treatment of Refractory Nausea and Vomiting: A Case Report and Review of the Literature. <i>Journal of Pain and Palliative Care Pharmacotherapy</i> , 2015, 29, 148-152.	0.8	8
147	Lack of Documentation of Evidence-Based Prognostication in Cancer Patients by Inpatient Palliative Care Consultants. <i>Journal of Palliative Medicine</i> , 2015, 18, 382-385.	1.1	5
148	Predictors of Progression in High-Grade Appendiceal or Colorectal Peritoneal Carcinomatosis After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. <i>Annals of Surgical Oncology</i> , 2015, 22, 1716-1721.	1.5	54
149	Variable Patterns of Continuous Morphine Infusions at End of Life. <i>Journal of Palliative Medicine</i> , 2015, 18, 786-789.	1.1	12
150	Phase 1 Study of a Hecpidin Antagonist, LY2787106, in Cancer-Associated Anemia. <i>Blood</i> , 2015, 126, 537-537.	1.4	4
151	Inclusion criteria for cancer cachexia clinical trials: CT-defined skeletal muscle loss versus body weight loss.. <i>Journal of Clinical Oncology</i> , 2015, 33, 67-67.	1.6	2
152	Patterns of palliative care consultation among elderly cancer patients.. <i>Journal of Clinical Oncology</i> , 2015, 33, e17557-e17557.	1.6	0
153	When Open-Ended Questions Don't Work: The Role of Palliative Paternalism in Difficult Medical Decisions. <i>Journal of Palliative Medicine</i> , 2014, 17, 415-420.	1.1	65
154	Clinical Supervision: An Antidote to Personal and Team Compassion Fatigue (SA504). <i>Journal of Pain and Symptom Management</i> , 2014, 47, 447-448.	1.2	0
155	Age Disparity in Palliative Radiation Therapy Among Patients With Advanced Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 224-230.	0.8	40
156	Novel investigational biologics for the treatment of cancer cachexia. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 1113-1120.	3.1	17
157	Palliative Radiation Before Hospice: The Long and the Short of It. <i>Journal of Pain and Symptom Management</i> , 2014, 48, 1070-1079.	1.2	11
158	Implementing inpatient, evidence-based, antihistamine-transfusion premedication guidelines at a single academic US hospital. <i>Journal of Community and Supportive Oncology</i> , 2014, 12, 56-64.	0.1	7
159	Single-center, prospective pilot study to evaluate advance care planning implementing the 3 Questions and 3 Elements to identify an informed health care proxy in an outpatient oncology palliative care clinic.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS9655-TPS9655.	1.6	0
160	Predictors of progression in patients with high-grade appendiceal or colorectal adenocarcinoma after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.. <i>Journal of Clinical Oncology</i> , 2014, 32, e14573-e14573.	1.6	0
161	Rapidly progressive subcutaneous metastases from gallbladder cancer: insight into a rare presentation in gastrointestinal malignancies. <i>Journal of Gastrointestinal Oncology</i> , 2014, 5, E58-64.	1.4	5
162	Octreotide prescribing patterns in the palliation of symptomatic inoperable malignant bowel obstruction patients at a single US academic hospital. <i>Supportive Care in Cancer</i> , 2013, 21, 2817-2824.	2.2	8

#	ARTICLE	IF	CITATIONS
163	Redefining the Role of Paternalism in Palliative Medicine (SA511). Journal of Pain and Symptom Management, 2013, 45, 400.	1.2	0
164	Octreotide Prescribing Patterns in the Palliation of Symptomatic Inoperable Malignant Bowel Obstruction Patients at a Single US Academic Hospital (FR416-B). Journal of Pain and Symptom Management, 2013, 45, 373-374.	1.2	0
165	In Chemotherapy for Lung Cancer, Sometimes Less is More. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 232-235.	4.9	12
166	A single-center, retrospective chart review evaluating outpatient code status documentation in the EPIC electronic medical record for patients with advanced solid tumor cancer.. Journal of Clinical Oncology, 2013, 31, 242-242.	1.6	3
167	Re-evaluating the inpatient use of routine diphenhydramine transfusion premedication practices.. Journal of Clinical Oncology, 2013, 31, 164-164.	1.6	0
168	A single center, retrospective analysis evaluating aberrant drug behavior stratification utilizing the opioid risk tool in patients with cancer.. Journal of Clinical Oncology, 2013, 31, 167-167.	1.6	1
169	Early outcome of a phase I study of interrupted pulse dosed axitinib combined with FOLFOX or FOLFIRI in refractory metastatic colorectal cancer.. Journal of Clinical Oncology, 2012, 30, 473-473.	1.6	1
170	inSIRT trial: Single-center phase II study of yttrium-90 radioactive resin microspheres in the treatment of liver-predominant metastatic colorectal adenocarcinoma after failure of first-line combination chemotherapy.. Journal of Clinical Oncology, 2012, 30, 685-685.	1.6	0
171	Molecular predictors of treatment response in colon and gastric cancer.. Journal of Clinical Oncology, 2012, 30, 619-619.	1.6	0
172	Abstract 3692: Single center phase II study of yttrium-90 radioactive resin microspheres in the treatment of liver predominant metastatic colorectal adenocarcinoma after failure of 1st-line combination chemotherapy. , 2012, , .		0
173	inSIRT trial: Single-center phase II study of yttrium-90 radioactive resin microspheres in the treatment of liver-predominant metastatic colorectal adenocarcinoma after failure of first-line combination chemotherapy.. Journal of Clinical Oncology, 2012, 30, e14079-e14079.	1.6	1
174	Molecular predictors of treatment response in colon and gastric cancer.. Journal of Clinical Oncology, 2012, 30, e14069-e14069.	1.6	0
175	Early outcome of a phase II study of yttrium-90 radioactive resin microspheres in the treatment of colorectal adenocarcinoma metastatic to the liver after failure of first-line combination chemotherapy (inSIRT Trial).. Journal of Clinical Oncology, 2011, 29, 626-626.	1.6	0
176	Symptom control in stem cell transplantation: a multidisciplinary palliative care team approach. Part 1: Physical symptoms. The Journal of Supportive Oncology, 2010, 8, 100-16.	2.3	16
177	Symptom control in stem cell transplantation: a multidisciplinary palliative care team approach. Part 2: psychosocial concerns. The Journal of Supportive Oncology, 2010, 8, 179-83.	2.3	15
178	Current concepts in malignant bowel obstruction management. Current Oncology Reports, 2009, 11, 298-303.	4.0	55
179	Darkness is No More. Journal of Palliative Medicine, 2009, 12, 389-390.	1.1	0